You are here
Valens GroWorks Sets the Table for International Cannabis Markets -- CFN Media
SEATTLE, Aug. 02, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing the international ambitions of Valens GroWorks Corp. (CSE: VGW), which is looking far beyond Canada’s 36 million potential customers to the exponentially larger opportunities in the global market. A key component of the company’s international plan is to build and utilize facilities that comply with the European Union’s Good Manufacturing Practices (GMP) standards, currently the most stringent regulations in the world. ‘EudraLex’ is the term for these rules and regulations governing medicinal products, and compliance with EudraLex is the key to unlocking the global export potential of Canadian cannabis products.
Think of Canada as the pioneer of the global cannabis industry, the test market for government-licensed legal marijuana. Countries the world over are watching the Canadian experiment with interest as the wave of cannabis legalization, initially in the form of medical cannabis programs, builds momentum around the globe. European and South American countries seem to be leading the charge, but many of them don’t have the production and cultivation infrastructure in place to serve their nascent markets.
Facilities and Certifications
Valens runs a laboratory that holds a dealers license called Supra THC Services. Supra recently became the first cannabis-focused, licensed Canadian lab to achieve ISO 17025 accreditation for cannabis testing. This standard allows the lab’s test reports and certificates to be accepted internationally, validating the company’s testing results and processes for international trade. Supra is partnered with $90+ billion ThermoFisher Scientific to create a Centre of Excellence for Plant Based Medicine Analytics in its lab.
Supra recently moved into a second Valens subsidiary’s facility, Valens AgriTech. Valens AgriTech also holds a dealers license. With Supra more focused on testing and analytics, Valens AgriTech handles cannabis cultivation, processing, oil production, and sales of oils through licensed producers. AgriTech is also in the late stages of its application to become a licensed producer. The AgriTech campus is in the process of becoming Eudralex GMP certified, the importance of which has been noted above.
The third Valens subsidiary, Valens Farms, is a joint venture with a real estate development company, in the process of constructing a 400,000 square foot greenhouse cultivation and production facility. The company expects to plant the first crop by the end of 2018, and the cannabis produced there will provide the raw material for the state-of-the-art extraction and production at the Valens AgriTech site. This greenhouse is being built from the ground up to EudraLex standards, ensuring the company’s ability to export products around the world once all of the proper licenses and certifications have been achieved. Valens Farms also has the option to build another 400,000 sf greenhouse at the site should the need arise.
The International Opportunity
Germany is home to about 83 million people, more than twice the population of Canada. It is also home to a medical marijuana program, covered by national health insurance, that is just getting off the ground. The country has experienced hiccups in permitting its own cultivation, and companies from Canada and the Netherlands are swooping in to satisfy soaring demand.
Italy, with a population of about 60 million, adopted a medical program in 2013. Strangely, the cultivation of cannabis there remains illegal, though the country recently introduced regulations allowing for some hemp cultivation. The Italian army is responsible for the country’s legal medical production capacity, totaling 220 pounds of output for the entire country in 2017. Supply and demand forces there will likely force change. Norway, Greece, Poland, Switzerland, even the United Kingdom have very recently implemented, or are in the process of implementing, some form of legal medical cannabis. In many places, the focus is on allowing medicines that have very low levels of THC.
South America is another leading market for cannabis and cannabis-derived products. In 2014, Uruguay became the first country in the world to fully legalize, though the rollout has come in fits and starts. Medical cannabis programs were established by Chile in 2014, Colombia in 2015, and Peru in 2017. Brazil has allowed the use of certain medicines for a few indications, and some provinces in Argentina allow for medicinal use.
The Valens Plan
Multi-subsidiary, multi-licensed Valens GroWorks is creating a vertically integrated, quality controlled, interdependent and complementary company that is primed to launch into lucrative international markets. Utilizing its scientific approach and certified commitment to strict quality standards throughout its processes, the company stands ready to provide cannabis and cannabis-derived products to emerging markets that employ even the most stringent regulations. Valens plans to take advantage of its experience in the world’s most mature cannabis market, Canada, parlaying that experience into market opportunities that dwarf those in its own country. Stay tuned.
Please follow the link to read the full article: http://www.cannabisfn.com/valens-groworks-sets-table-international-cannabis-markets/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/